Mito-apocynin(C11)，基于三苯基膦酸(TPP+)的线粒体靶向化合物，并具有口服性的化合物。Mito-apocynin(C11)由Apocynin部分与TPP+阳离子结合而合成。Mito-apocynin(C11)选择性靶向线粒体，具有神经保护作用。Mito-apocynin(C11)可预防嗅觉减退，纠正运动功能的缺陷。
Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function[1].
Mito-apocynin-C11 (3 mg/kg; oral gavage; 3x/wk from 3 months of age until 15 months) markedly improves the coordinated motor function and olfactory function in LRRK2R1441G mice[1]. Animal Model: LRRK2R1441G mice[1]
[1]. Dranka BP, et al. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci Lett. 2014 Nov 7;583:159-64.
动态评分
0.0